Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2016 | editorial

Rationale of an economically driven PD1 biomarker development in lung cancer—an academic dilemma

verfasst von: Wolfgang Hilbe, MD, Rupert Bartsch, MD, Christoph Zielinski, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Excerpt

Immunotherapies for second line use in lung cancer have proven to add relevant value compared to standard treatment options [1‐3]; indeed, they are deemed a breakthrough in cancer treatment. The “clinical value” of a certain drug is determined by its effects on relevant endpoints, namely overall survival, tolerability, and quality of life. From a historical perspective, at least two of these three endpoints should be achieved to accept a new treatment option to be beneficial. Monoclonal antibodies targeting the PD1 and PD-L1 receptors have achieved these endpoints. Due to their mode of action the presence of these targets should—per definition—be prerequisite for their clinical application. However, the short history of “targeted therapies” has told us to be cautious and that simplified explanations of potential drug effects were sometimes misleading. …
Vorheriger Artikel ASH 2015—insights and outlooks
Nächster Artikel Novel strategies in the management of chronic lymphocytic leukemia (CLL)
Literatur
1.
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.CrossRefPubMedPubMedCentral
2.
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.CrossRefPubMed
3.
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.CrossRefPubMed
4.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.CrossRefPubMed
5.
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.CrossRefPubMed
6.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.CrossRefPubMed
7.
Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 2003;21(12):2237–46.CrossRefPubMed
8.
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527–37.CrossRefPubMed
9.
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.CrossRefPubMed
10.
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.CrossRefPubMed
11.
Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21(5):634–42.CrossRefPubMedPubMedCentral
12.
Sul J, Blumenthal GM, Jiang X, et al. FDA approval summary: Pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand. Oncologist. 2016;21(5):643–50.CrossRefPubMedPubMedCentral
Metadaten
Titel
Rationale of an economically driven PD1 biomarker development in lung cancer—an academic dilemma
verfasst von
Wolfgang Hilbe, MD
Rupert Bartsch, MD
Christoph Zielinski, MD
Publikationsdatum
01.09.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0281-5

Weitere Artikel der Ausgabe 3/2016

Healthcare resource utilization and G‑CSF use in patients with solid tumors or hematological malignancies hospitalized for febrile neutropenia in Bulgaria, Czech Republic and Slovakia

  • original report

Acute myeloid leukemia: highlights from ASH 2015

  • short review

A welcome statement from the associate Editor-in-Chief

  • editorial

Antiangiogenic therapies in ovarian cancer

  • Open Access
  • short review

Welcome to the new associate Editor-in-Chief of memo

  • editorial

Indolent lymphoma at ASH 2015: new treatment approaches

  • short review